References: Merkel Cell Skin Cancer

Albores-Saavedra J, Batich K, Chable-Montero F, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: A population based study. J Cutan Pathol. 2010;37:20-27.

American Joint Committee on Cancer. Merkel Cell Carcinoma. In: AJCC Cancer Staging Manual. 7^th ed. New York, NY: Springer; 2010:315-323.

Christensen SR, Leffell DJ. Chapter 92: Cancer of the Skin. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

Ely H, Pascucci A. Merkel cell carcinoma: Treatment with bleomycin. Dermatol Online J. 2008;14:3.

Fitzgerald TL, Dennis S, Kachare SD, et al. Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg. 2015;81:802-806.

Gupta SG, Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol. 2006;142:685-690.

Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory
metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374-1385.

Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63:751-761.

Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options Oncol. 2013;14:249-263.

National Cancer Institute. Physician Data Query (PDQ). Merkel Cell Carcinoma Treatment. 2015. Accessed at www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq on April 7, 2016.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Merkel Cell Carcinoma. Version 1.2016. Accessed at www.nccn.org/professionals/physician_gls/pdf/mcc.pdf on April 7, 2016.

Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with pembrolizumab in advanced
Merkel-cell carcinoma. N Engl J Med. 2016;374:2542-2552.

Paulson KG, Iyer JG, Blom A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol. 2013;133:642-646.

Rodig SJ, Cheng J, Wardzala J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest. 2012;122:4645-4653.

Rollison DE, Giuliano AR, Becker JC. New virus associated with Merkel cell carcinoma development. J Natl Compr Canc Netw. 2010;8:874-880.

Wood GS, Xu YG, Aylward JL, et al. Chapter 70: Nonmelanoma skin cancers: Basal cell and squamous cell carcinomas. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

Young JL, Ward KC, Ries LAG. Cancers of rare sites. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.